Health

STAT+: Pharmalittle: We’re reading about a generic HIV prevention shot, Lonza buying U.S. facilities, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 03/11/2026, 14:51:25 UTC.

Briefings

The U.S. FDA granted tentative approval for Dr. Reddy’s Laboratories to manufacture a generic HIV prevention medicine, with shipping expected next month. Simultaneously, Lonza agreed to acquire five U.S. manufacturing sites from Merck KGaA, expanding its footprint to nine facilities across Missouri, Wisconsin, Indiana, and California. This acquisition aims to accelerate the availability of the drug in low- and middle-income countries, with the annual cost per person estimated at $40. The article notes the company’s ongoing strategy to build a global contract manufacturing network through acquisitions.

Key points

• Dr. Reddy’s Laboratories received tentative FDA approval to produce a generic HIV prevention medicine, with shipping scheduled for next month.
• Lonza acquired five U.S. manufacturing sites from Merck KGaA, increasing its U.S. site count to nine and expanding its capabilities in the U.S.

Context

This finding highlights a significant expansion in global drug manufacturing capabilities, specifically for HIV prevention, alongside Lonza’s strategic acquisition of U.S. facilities to enhance its production capacity for advanced cancer and gene therapies.

Limitations

The evidence is limited to the provided article excerpt, which does not include the full story or additional background context. The article explicitly states to continue reading for the full story, meaning the complete impact and details are not available in this source.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/11/2026, 14:59:49 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifsyn2j3nk6kshghwlj2lkt4nfvmk5ojex3hivzh2xu3zecfmrwoe